Overview


According to FutureWise analysis the market for urinary ph modifiers in 2023 is US$ 2.42 billion, and is expected to reach US$ 3.32 billion by 2031 at a CAGR of 4%.

Urinary pH modifiers are chemicals that increase the pH of urine. They increase the alkalinity of urine, which helps to prevent kidney stones. The kidneys are aided in the elimination of pollutants by making urine more alkaline. Potassium acid phosphate, sodium bicarbonate, sodium citrate, and potassium citrate are examples of urinary pH modifiers used in the treatment of genitourinary diseases. Certain disorders, the most prevalent of which is urolithiasis, can be induced or worsened by the pH of urine. In the treatment and prevention of such illnesses, the use of drugs that affect urine pH is usually recommended. The increased prevalence of renal failure is expected to have an impact on the growth of the urinary pH modifiers market. Urinary tract infections are particularly common in diabetic patients. Women are particularly prone to this condition due to the short length of the urethra, which allows bacteria to enter more easily. An increase in the number of new product launches, the number of mergers and acquisitions is increasing which will further fuel the market growth. The high costs of drug development and distribution, on the other hand, will slow the market's growth rate. The urinary pH modifiers market will be challenged by a shortage of experienced experts and a lack of healthcare infrastructure in developing economies. Furthermore, the rising number of counterfeit pharmaceuticals and a lack of public awareness about the infection and drugs will function as market restraints, slowing the market's growth rate.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Urinary pH Modifiers Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Urinary pH Modifiers Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • GlaxoSmithKline, plc.
  •  Johnson and Johnson Private Limited
  • Eli Lilly and Company
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Melinta Therapeutics Llc
  • MerckCo., Inc.
  • AstraZeneca
  • Ionis Pharmaceuticals
  • Genentech Inc
  • Bristol-Myers Squibb Company
  • Allergan
  • Cipla Inc.
  • Astellas Pharma Inc.
  • Bayer AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Indication

  • Alkalosis
  • Alkylating Agent Cystitis
  • Asystole
  • Gastroesophageal reflux disease (GERD)
  • Diabetic Ketoacidosis
  • Hyperkalemia
  • Hyponatremia
  • Indigestion
  • Metabolic Acidosis
  • Nephrolithiasis
  • Urinary Acidification
  • Urinary Alkalinization
  • Others

By Drug

  • Potassium Acid Phosphate
  • Sodium Bicarbonate
  • Sodium Citrate
  • Potassium Citrate

By Dosage

  • Injection
  • Tablets
  • Solution
  • Powder
  • Others

By Route of Administration

  • Intravenous
  • Extracorporeal
  • Oral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Urinary pH Modifiers Market By Indication, By Drug, By Dosage, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Urinary pH Modifiers Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Urinary pH Modifiers Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Urinary pH Modifiers Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Urinary pH Modifiers Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Alkalosis
        2. Alkylating Agent Cystitis
        3. Asystole
        4. Gastroesophageal reflux disease (GERD)
        5. Diabetic Ketoacidosis
        6. Hyperkalemia
        7. Hyponatremia
        8. Indigestion
        9. Metabolic Acidosis
        10. Nephrolithiasis
        11. Urinary Acidification
        12. Urinary Alkalinization
        13. Others

  • 8.   Urinary pH Modifiers Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Potassium Acid Phosphate
        2. Sodium Bicarbonate
        3. Sodium Citrate
        4. Potassium Citrate

  • 9.   Urinary pH Modifiers Market, By Dosage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Tablets
        3. Solution
        4. Powder
        5. Others

  • 10.   Urinary pH Modifiers Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravenous
        2. Extracorporeal
        3. Oral
        4. Others

  • 11.   Urinary pH Modifiers Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 12.   Urinary pH Modifiers Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.   North America Urinary pH Modifiers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Urinary pH Modifiers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Urinary pH Modifiers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Urinary pH Modifiers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Sanofi
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Teva Pharmaceutical Industries Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline, plc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson & Johnson Private Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Eli Lilly and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Abbott
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. F. Hoffmann-La Roche Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Mylan N.V.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Melinta Therapeutics Llc
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. MerckCo., Inc.
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. AstraZeneca
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Ionis Pharmaceuticals
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Genentech Inc
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Bristol-Myers Squibb Company
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Allergan
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Cipla Inc.
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
          19. Astellas Pharma Inc.
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
         20. Bayer AG
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients